New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Abstract
We investigated the coagulation effects in vitro of exogenous oxytocin in whole blood of healthy term parturients.Thromboelastography (TEG®) was performed on kaolin-activated citrated blood samples from 25 healthy, term, nonlaboring parturients. We compared the in vitro effects on the maternal thromboelastographic profile of 3 different exogenous oxytocin concentrations (22.5, 30.1, and 32.9 µU/mL) and a control (0 µU/mL). These exogenous oxytocin concentrations were chosen to approximate maternal plasma oxytocin concentrations during elective cesarean delivery, vaginal delivery, and nonelective cesarean delivery, respectively.Increasing the oxytocin concentration was significantly associated with hypercoagulable effects as observed with TEG® (decreasing reaction time, clot formation time, and Tmax; increasing a angle and maximum rate of thrombus generation). Compared with control samples, the median percentage change (interquartile range) in TEG® values for samples with the highest exogenous oxytocin concentration (32.9 µU/mL) was largest for reaction time: -40.3% (-45.8%, -22.2%); and Tmax: -39.2% (-42.9%, -28.5%).The results of this in vitro investigation suggest that exogenous oxytocin is associated with modest hypercoagulable effects in the maternal blood of healthy term parturients.
View details for DOI 10.1213/ANE.0b013e3182222a82
View details for Web of Science ID 000293064500019
View details for PubMedID 21642611